[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415052":3},{"organization":4,"armGroups":7,"interventions":50,"overallOfficials":57,"centralContacts":62,"locations":71,"responsibleParty":92,"collaborators":94,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":56,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":108,"minAge":109,"maxAge":56,"enrollmentInfo":110,"targetDuration":56,"studyType":113,"phases":114,"briefSummary":117,"conditions":118,"keywords":130,"overallStatus":74,"whyStopped":56,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Thomas Advanced Medical LLC","INDUSTRY",[8,14,18,22,26,30,34,38,42,46],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Autoimmune Diseases","EXPERIMENTAL","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],"Biological: PrimePro™\u002F PrimeMSK™",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: Cardiovascular Disorders","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3: Diabetes Complications","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Arm 4: Integumentary Disease","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Arm 5: Musculoskeletal Disorders","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Arm 6: Neurodegenerative Disorders","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Arm 7: Pulmonary Disorders","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":39,"type":10,"description":40,"interventionNames":41},"Arm 8: Sexual Dysfunction","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":43,"type":10,"description":44,"interventionNames":45},"Arm 9: Urologic Disorders","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],{"label":47,"type":10,"description":48,"interventionNames":49},"Arm 10: Viral Illnesses","Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions.",[13],[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"BIOLOGICAL","PrimePro™\u002F PrimeMSK™","Injection via condition specific route of administration.",[47,9,15,19,23,27,31,35,39,43],null,[58],{"name":59,"affiliation":60,"role":61},"Ernst R Von Schwarz, MD, PhD","HeartStem Institute, Southern California Hospital at Culver City","PRINCIPAL_INVESTIGATOR",[63,68],{"name":64,"role":65,"phone":66,"phoneExt":56,"email":67},"Paul C Bogaardt, PhD(c), MSc, MBA","CONTACT","866 864 7789","paul@thomasadvancedmedical.com",{"name":69,"role":65,"phone":66,"phoneExt":56,"email":70},"Karen Mulholland Angelus","karen@thomasadvancedmedical.com",[72],{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Southern California Hospital at Culver City \u002F Southern California Hospital at Hollywood \u002F Multiple US-based Sub-Investigator Sites","RECRUITING","Culver City","California","92032","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-118.39647,34.02112,{"lat":84,"lon":83},[87,90],{"name":69,"role":65,"phone":88,"phoneExt":56,"email":89},"866-864-7789","info@thomasadvancedmedical.com",{"name":91,"role":65,"phone":66,"phoneExt":56,"email":89},"Ernst R Von Shwarz, MD PhD",{"type":93,"investigatorFullName":56,"investigatorTitle":56,"investigatorAffiliation":56,"oldNameTitle":56,"oldOrganization":56},"SPONSOR",[95,98],{"name":96,"class":97},"HeartStem Institute","UNKNOWN",{"name":99,"class":97},"NuStem","100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052",false,"NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",true,"ALL","18 Years",{"count":111,"type":112},5000,"ESTIMATED","INTERVENTIONAL",[115,116],"PHASE1","PHASE2","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[119,120,121,122,123,124,125,126,127,128,129],"Autoimmune Diseases","Cardiovascular Disorders","Diabetes Complications","Integumentary Disease","Musculoskeletal Disorders","Neurodegenerative Disorders","Neurologic Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":160,"type":161},"2022-04-29","ACTUAL",{"date":163,"type":161},"2020-07-09",{"date":165,"type":112},"2030-12-09",{"name":5,"class":6},1]